Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy
Background. Treatment of splenic marginal zone lymphoma (SMZL) patients is not
standardized. Recent data suggest that rituximab is highly effective and could be considered …
standardized. Recent data suggest that rituximab is highly effective and could be considered …
Rituximab monotherapy is highly effective in splenic marginal zone lymphoma
C Kalpadakis, GA Pangalis… - Hematological …, 2007 - Wiley Online Library
Splenectomy has traditionally been considered as a standard first line treatment for splenic
marginal zone lymphoma (SMZL) conferring a survival advantage over chemotherapy …
marginal zone lymphoma (SMZL) conferring a survival advantage over chemotherapy …
Treatment of splenic marginal zone lymphoma
Splenic marginal zone lymphoma (SMZL) is a distinct lymphoma entity characterized by an
indolent clinical course and prolonged survival. Treatment is not standardized, since there …
indolent clinical course and prolonged survival. Treatment is not standardized, since there …
Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma
M Else, A Marín‐Niebla, F de la Cruz… - British journal of …, 2012 - Wiley Online Library
Splenic marginal zone lymphoma (SMZL) is a rare B‐cell malignancy, with no standard
treatment other than splenectomy. Rituximab has shown encouraging results. We therefore …
treatment other than splenectomy. Rituximab has shown encouraging results. We therefore …
Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab
M Bennett, GP Schechter - Seminars in hematology, 2010 - Elsevier
Splenic marginal zone lymphoma (SMZL) is an uncommon indolent B-cell lymphoma
causing marked splenic enlargement with CD20-rich lymphoma cells infiltrating blood and …
causing marked splenic enlargement with CD20-rich lymphoma cells infiltrating blood and …
Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned?
C Kalpadakis, GA Pangalis… - Leukemia & …, 2014 - Taylor & Francis
Splenic marginal zone lymphoma (SMZL) is a rare chronic B-cell lymphoproliferative
disorder recognized as a distinct entity in the World Health Organization (WHO) …
disorder recognized as a distinct entity in the World Health Organization (WHO) …
Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a …
Rituximab® provides high response rates and effective disease palliation in patients with
splenic marginal zone lymphoma (SMZL). We conducted a phase II trial in patients with …
splenic marginal zone lymphoma (SMZL). We conducted a phase II trial in patients with …
Rituximab monotherapy for splenic marginal zone lymphoma
M Bennett, K Sharma, S Yegena, I Gavish… - …, 2005 - haematologica.org
In this retrospective study, rituximab was found to be effective therapy in 10 of 11 patients
with splenic marginal zone lymphoma, inducing prompt reduction in splenomegaly …
with splenic marginal zone lymphoma, inducing prompt reduction in splenomegaly …
Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone
AM Tsimberidou, D Catovsky, E Schlette… - … Journal of the …, 2006 - Wiley Online Library
BACKGROUND The optimal management of patients with splenic marginal zone
lymphoma/marginal zone lymphoma (SMZL) is controversial. The objective of this …
lymphoma/marginal zone lymphoma (SMZL) is controversial. The objective of this …
Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia
KH Xing, A Kahlon, BF Skinnider… - British journal of …, 2015 - Wiley Online Library
Splenic marginal zone lymphoma (SMZL) accounts for less than 2% of all non‐Hodgkin
lymphomas. We identified 107 cases diagnosed with SMZL between 1985 and 2012 from …
lymphomas. We identified 107 cases diagnosed with SMZL between 1985 and 2012 from …